Public-records dataset of 15 major US compounding pharmacies serving telehealth and DTC health operators in 2026. 503A vs 503B classification, specialty focus, recent FDA enforcement history, and state-specific rules — consolidated so operators can evaluate compounding partners without monitoring 50 state pharmacy boards and the FDA enforcement database individually.
Operators: cross-reference your current compounding partner against this dataset. Attorneys, journalists, researchers: cite freely.
9 locations; PCAB/NABP/LegitScript accredited. Supplied Hims & Hers GLP-1 until Feb 2025 split after oral semaglutide controversy. Sued by Eli Lilly April 2025; filed antitrust countersuit against Lilly + Novo Jan 2026. AZ Board of Pharmacy inspection Sept 2025 cited continued single-ingredient GLP-1 compounding after shortage exemption ended.
Company siteDescribed as North America's largest compounding facility. FDA Form 483 May 2024 (fill weight discrepancies in semaglutide). FDA Warning Letter April 2025 (insanitary conditions in sterile prep). Sued by Eli Lilly July 2025. Co-filed tirzepatide patent challenge with BPI Labs.
Company siteOnly FDA-registered drug manufacturer also operating a 503B GLP-1 line. Robotic aseptic filling, in-house batch testing. FDA Form 483 Feb 2025 cited missing 'Office Use Only' labeling on semaglutide/tirzepatide vials. Joined Empower in tirzepatide patent challenge.
Company site60,000 sq ft facility, PCAB-accredited. FDA Warning Letter March 2020 (no valid patient-specific prescriptions, insanitary conditions); closeout May 2022. Confirmed partner of Zappy Health and other telehealth platforms.
Company siteOnly 503B outsourcing facility in Central FL. Opened sister facility Wesley Pharmaceuticals May 2025, scaling from 150K to 450K vials/week. FDA Form 483 May 2024 (semi-annual reporting failure, not sterility). Currently compounds liraglutide; dropped sema/tirz after shortage end.
Company site20,500 sq ft 503A + 20,000 sq ft FDA-registered 503B outsourcing facility. Best known for sterile hormone pellet implants. Not a primary GLP-1 telehealth supplier; serves 49 states + Puerto Rico per company.
Company siteOperates 6 x 503A pharmacies and 2 x 503B outsourcing facilities. Hormone-focused rather than GLP-1 primary. Ships nationwide since 1985.
Company site54,000 sq ft 503A in Tampa + 30,000 sq ft 503B in Las Vegas. Owned by Fagron (global compounding leader). Multi-specialty supplier to telehealth and aesthetic platforms.
Company siteFDA Class I recall April 2024: mislabeled tirzepatide vials actually contained testosterone cypionate. Significant patient-safety enforcement event triggering ongoing litigation exposure.
Company sitePleaded guilty federally to distributing unapproved new drugs (SARMs, BPC-157, CJC-1295, ipamorelin, melanotan II, etc.); forfeited $1.78M. Acquired by Noom to fuel weight-loss expansion. Notable federal criminal-enforcement history.
Company siteAcquired by Fagron January 2026. Not primarily a GLP-1 telehealth supplier; broad specialty 503A compounder.
Company siteFDA Warning Letter Sept 2021; second FDA Warning Letter Dec 2024 citing serious sterile-prep deficiencies. Repeat enforcement target.
Company siteUSP 795/797/800 compliant. Tirzepatide formulated with glycine. Nationwide telehealth shipping.
Company siteAcquired by Eden Health Aug 2025; now Eden's in-house captive 503A. Sterile hazardous lab opens to third-party telehealth partners in underserved states.
Company siteTelehealth-integrated. Former Eden Health partner pharmacy. Each prescription accompanied by Certificate of Analysis.
Company sitePublic-records timeline of FDA, state pharmacy board, and litigation events affecting compounding pharmacies serving telehealth operators. Sourced from FDA Form 483 / Warning Letter database, state board orders, and court filings.
FDA formally proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list permanently — 503B facilities can no longer compound these from bulk.
FDA clarified that 503A patient-specific compounding of GLP-1 medications can continue with documented medical need (limit ~4 prescriptions/month of same formulation per pharmacy).
Sterility and potency failures in sema/tirz compounding.
Mass enforcement wave citing false 'generic'/'same active ingredient' claims in compounded GLP-1 marketing.
Continued single-ingredient sema/tirz compounding cited after FDA shortage exemption ended.
Novo Nordisk filed multi-defendant suit over compounded semaglutide marketing and sourcing.
Eli Lilly sued Empower in S.D. Texas over compounded tirzepatide.
Insanitary conditions in sterile drug prep, microbial contamination response failures.
Missing 'Office Use Only' labeling on sema/tirz vials.
FDA declared semaglutide shortage resolved; 60-90 day compounding wind-down clock started.
Repeat sterile-prep deficiencies, second Warning Letter.
FDA declared tirzepatide shortage resolved; compounding wind-down clock started.
503B violations cited during inspection.
Failure to file required 503B semi-annual product identification reports.
Fill weight discrepancies in semaglutide vials, inadequate QC sampling, aseptic processing deficiencies.
Mislabeled tirzepatide vials actually contained testosterone cypionate.
States with distinctive compounding regulations or enforcement priorities that affect out-of-state pharmacies shipping to their residents.
Medical board rule restricts weight-loss prescribing to FDA-approved-for-weight-loss drugs only — effectively bans compounded GLP-1 for weight loss.
AB 1990 — pharmaceutical-grade ingredient certifications required; fines up to $1,000/dose plus license revocation for non-compliance.
Among the strictest nonresident sterile/complex non-sterile compounding licensure regimes; requires disclosure of out-of-state enforcement actions on application and renewal.
$250 annual per-pharmacist registration fee for nonresident compounders/dispensers (2024 rule).
Class E-S nonresident sterile compounding permits require recent third-party inspection report from approved vendor.
This dataset is free for healthcare attorneys, journalists, compliance officers, researchers, and operators to cite, reference, or link. We aggregate from public records (FDA, state pharmacy boards, court filings, press releases) and consolidate so the data is usable.
TrueEval Compounding Pharmacy Compliance Map. https://trueeval.com/compounding-pharmacy-map. Accessed November 20, 2026.Submit corrections or new enforcement events: (844) 771-7836
Five free 60-second compliance trackers score your operation against the deficiencies state boards most-frequently cite. Pick the closest to your vertical:
Compounded GLP-1 programs
View toolMedspa / injectables / lasers
View toolTRT, peptides, hormone optimization
View toolIV bars, mobile IV, hydration
View toolPC + MSO healthcare structures
View toolLive state + federal action feed
View toolMethodology: Evidence sourced from state medical board orders, pharmacy board actions, DEA bulletins, FDA guidance, and published statutes. AI-assisted summarization; scoring is deterministic. Scope: Informational only — not legal, accounting, or medical advice. No attorney-client, accountant-client, or provider-patient relationship is established.